Final results from the Phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves survival for women with newly diagnosed advanced ovarian cancer.
The study found that median overall survival increased by 14.7 months with IMNN-001 plus chemotherapy compared to chemotherapy alone (45.1 vs. 30.4 months). For patients who also received PARP inhibitor maintenance therapy, the survival benefit was even greater, with an increase of 24.2 months (65.6 vs. 41.4 months). The treatment was well tolerated, with no new safety concerns reported.
IMNN-001 is delivered directly into the abdomen and works by stimulating the body to produce Interleukin-12 (IL-12), which activates T-cells and natural killer cells to attack the tumor locally while limiting systemic side effects.
Building on these results, the Phase 3 OVATION 3 trial is now recruiting patients. This pivotal study aims to confirm the survival benefit and support FDA approval, with overall survival as its main endpoint.